UB TT430
Alternative Names: UB-TT430Latest Information Update: 18 Nov 2022
At a glance
- Originator Umoja Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Oct 2022 Preclinical trials in Solid tumours in USA (unspecified route)(Umoja Biopharma pipeline; Before October 2022)